TOKYO - Japan's health ministry Tuesday approved the use of a COVID-19 vaccine developed by U.S. biotechnology firm Novavax Inc., with deliveries of the drug to local governments expected to start in late May, and shots might also begin that month.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
